Scaling CRISPR for Rare Disease with Aurora Therapeutics' Dr. Edward Kaye

We love to hear from our listeners. Send us a message. On episode 124 of Cell & Gene: The Podcast, Aurora Therapeutics' CEO Dr. Edward Kaye discusses the company’s strategy for translating CRISPR gene editing into scalable, commercially viable medicines for rare diseases. Aurora is initially targeting phenylketonuria (PKU) using a platform approach that leverages shared components, such as lipid nanoparticles and base editors, while customizing guide RNAs for specific mutations. Dr. Kaye explains how trials, regulatory flexibility, and optimized manufacturing could make it possible to treat many genetic variants efficiently and cost-effectively. Ultimately, Aurora aims to build a repeatable model that expands gene editing access to larger rare-disease populations while keeping patients at the center of development.

You can listen to Scaling CRISPR for Rare Disease with Aurora Therapeutics' Dr. Edward Kaye online on Radio and Podcast. Open the player on this page to stream the available audio.

Scaling CRISPR for Rare Disease with Aurora Therapeutics' Dr. Edward Kaye is an episode from Cell & Gene: The Podcast by Erin Harris.

This episode is 28:04 long.

This episode was published on Mar 12, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Cell & Gene: The Podcast when more episodes are available from the podcast feed.